Tina Jorsal1,2, Nicolai J Wewer Albrechtsen3,4,5,6, Marie M Christensen1,2, Brynjulf Mortensen1, Erik Wandall7, Ebbe Langholz7, Steffen Friis7, Dorte Worm8, Cathrine Ørskov3, René K Støving9, Alin Andries10, Claus B Juhl10, Frederik Sørensen11, Julie L Forman11, Mechthilde Falkenhahn12, Petra B Musholt12, Stefan Theis12, Philip J Larsen12, Jens J Holst3,4, Niels Vrang13, Jacob Jelsing13, Tina Vilsbøll1,2,14, Filip K Knop1,2,4,14. 1. Center for Clinical Metabolic Research, Gentofte Hospital, University of Copenhagen, Hellerup, Denmark. 2. Steno Diabetes Center Copenhagen, Gentofte, Denmark. 3. Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark. 4. Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark. 5. Novo Nordisk Foundation Center for Protein Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark. 6. Department of Clinical Biochemistry, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark. 7. Endoscopic Unit, Gentofte Hospital, University of Copenhagen, Hellerup, Denmark. 8. Department of Medicine, Amager Hospital, University of Copenhagen, Copenhagen, Denmark. 9. Elite Research Center for Medical Endocrinology & Center for Eating Disorders, Odense University Hospital, Odense, Denmark. 10. Surgical Unit, Sydvestjysk Sygehus, Esbjerg, Denmark. 11. Section of Biostatistics, Department of Public Health, University of Copenhagen, Copenhagen, Denmark. 12. Sanofi Aventis, Frankfurt, Germany. 13. Gubra, Hørsholm, Denmark. 14. Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
Abstract
CONTEXT: After Roux-en-Y gastric bypass (RYGB) surgery, postprandial plasma glucagon concentrations have been reported to increase. This occurs despite concomitant improved glucose tolerance and increased circulating plasma concentrations of insulin and the glucagon-inhibiting hormone glucagon-like peptide 1 (GLP-1). OBJECTIVE: To investigate whether RYGB-induced hyperglucagonemia may be derived from the gut. DESIGN AND SETTING: Substudy of a prospective cross-sectional study at a university hospital in Copenhagen, Denmark. PARTICIPANTS: Morbidly obese individuals undergoing RYGB (n = 8) with or without type 2 diabetes. INTERVENTIONS: Three months before and after RYGB, participants underwent upper enteroscopy with retrieval of gastrointestinal mucosal biopsy specimens. Mixed-meal tests were performed 1 week and 3 months before and after RYGB. MAIN OUTCOME MEASURES: The 29-amino acid glucagon concentrations in plasma and in mucosal gastrointestinal biopsy specimens were assessed using mass spectrometry-validated immunoassays, and a new monoclonal antibody reacting with immunoreactive glucagon was used for immunohistochemistry. RESULTS: Postprandial plasma concentrations of glucagon after RYGB were increased. Expression of the glucagon gene in the small intestine increased after surgery. Glucagon was identified in the small-intestine biopsy specimens obtained after, but not before, RYGB. Immunohistochemically, mucosal biopsy specimens from the small intestine harbored cells costained for GLP-1 and immunoreactive glucagon. CONCLUSION: Increased concentrations of glucagon were observed in small-intestine biopsy specimens and postprandially in plasma after RYGB. The small intestine harbored cells immunohistochemically costaining for GLP-1 and glucagon-like immunoreactivity after RYGB. Glucagon derived from small-intestine enteroendocrine l cells may contribute to postprandial plasma concentrations of glucagon after RYGB.
CONTEXT: After Roux-en-Y gastric bypass (RYGB) surgery, postprandial plasma glucagon concentrations have been reported to increase. This occurs despite concomitant improved glucose tolerance and increased circulating plasma concentrations of insulin and the glucagon-inhibiting hormone glucagon-like peptide 1 (GLP-1). OBJECTIVE: To investigate whether RYGB-induced hyperglucagonemia may be derived from the gut. DESIGN AND SETTING: Substudy of a prospective cross-sectional study at a university hospital in Copenhagen, Denmark. PARTICIPANTS: Morbidly obese individuals undergoing RYGB (n = 8) with or without type 2 diabetes. INTERVENTIONS: Three months before and after RYGB, participants underwent upper enteroscopy with retrieval of gastrointestinal mucosal biopsy specimens. Mixed-meal tests were performed 1 week and 3 months before and after RYGB. MAIN OUTCOME MEASURES: The 29-amino acid glucagon concentrations in plasma and in mucosal gastrointestinal biopsy specimens were assessed using mass spectrometry-validated immunoassays, and a new monoclonal antibody reacting with immunoreactive glucagon was used for immunohistochemistry. RESULTS: Postprandial plasma concentrations of glucagon after RYGB were increased. Expression of the glucagon gene in the small intestine increased after surgery. Glucagon was identified in the small-intestine biopsy specimens obtained after, but not before, RYGB. Immunohistochemically, mucosal biopsy specimens from the small intestine harbored cells costained for GLP-1 and immunoreactive glucagon. CONCLUSION: Increased concentrations of glucagon were observed in small-intestine biopsy specimens and postprandially in plasma after RYGB. The small intestine harbored cells immunohistochemically costaining for GLP-1 and glucagon-like immunoreactivity after RYGB. Glucagon derived from small-intestine enteroendocrine l cells may contribute to postprandial plasma concentrations of glucagon after RYGB.
Authors: Isabella Jonsson; Kirstine N Bojsen-Møller; Viggo B Kristiansen; Simon Veedfald; Nicolai J Wewer Albrechtsen; Trine R Clausen; Rune E Kuhre; Jens F Rehfeld; Jens J Holst; Sten Madsbad; Maria S Svane Journal: Front Endocrinol (Lausanne) Date: 2021-05-14 Impact factor: 5.555
Authors: Petros Katsogiannos; Prasad G Kamble; Urban Wiklund; Magnus Sundbom; Daniel Espes; Ulf Hammar; F Anders Karlsson; Maria J Pereira; Jan W Eriksson Journal: Endocrine Date: 2020-01-26 Impact factor: 3.633
Authors: Carolina B Lobato; Sofia S Pereira; Marta Guimarães; Bolette Hartmann; Nicolai J Wewer Albrechtsen; Linda Hilsted; Jens J Holst; Mário Nora; Mariana P Monteiro Journal: Front Endocrinol (Lausanne) Date: 2020-11-30 Impact factor: 5.555
Authors: Kleopatra Alexiadou; Joyceline Cuenco; James Howard; Nicolai Jacob Wewer Albrechtsen; Ibiyemi Ilesanmi; Anna Kamocka; George Tharakan; Preeshila Behary; Paul R Bech; Ahmed R Ahmed; Sanjay Purkayastha; Robert Wheller; Matthieu Fleuret; Jens Juul Holst; Stephen R Bloom; Bernard Khoo; Tricia M-M Tan Journal: BMJ Open Diabetes Res Care Date: 2020-03